Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pharming Group NV (PHAR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PHAR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30.67
1 Year Target Price $30.67
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.16% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 985.24M USD | Price to earnings Ratio - | 1Y Target Price 30.67 |
Price to earnings Ratio - | 1Y Target Price 30.67 | ||
Volume (30-day avg) 3 | Beta 0.56 | 52 Weeks Range 7.31 - 17.08 | Updated Date 10/17/2025 |
52 Weeks Range 7.31 - 17.08 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-22 | When Before Market | Estimate -0.125 | Actual - |
Profitability
Profit Margin -2.41% | Operating Margin (TTM) 3.27% |
Management Effectiveness
Return on Assets (TTM) 2.85% | Return on Equity (TTM) -3.7% |
Valuation
Trailing PE - | Forward PE 50.76 | Enterprise Value 1047366731 | Price to Sales(TTM) 2.9 |
Enterprise Value 1047366731 | Price to Sales(TTM) 2.9 | ||
Enterprise Value to Revenue 3.08 | Enterprise Value to EBITDA 35.48 | Shares Outstanding 68514762 | Shares Floating 670711932 |
Shares Outstanding 68514762 | Shares Floating 670711932 | ||
Percent Insiders - | Percent Institutions 0.09 |
Upturn AI SWOT
Pharming Group NV
Company Overview
History and Background
Pharming Group NV was founded in 1988. It is a biopharmaceutical company dedicated to developing and commercializing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and immune disorders.
Core Business Areas
- Hereditary Angioedema (HAE): Developing and marketing RUCONESTu00ae (recombinant C1 esterase inhibitor) for acute HAE attacks. It is the primary revenue driver. Pharming acquired all commercial rights to RUCONEST in the U.S. in 2022.
- Leniolisib (experimental): Developing leniolisib, a selective PI3Ku03b4 inhibitor, for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. It was approved in 2023 in the US and Europe.
Leadership and Structure
Sijmen de Vries is the Chief Executive Officer. The company has a supervisory board and an executive board. Its headquarters are in Leiden, Netherlands.
Top Products and Market Share
Key Offerings
- RUCONEST: RUCONESTu00ae (recombinant C1 esterase inhibitor) is used to treat acute angioedema attacks in patients with Hereditary Angioedema (HAE). It's a leading treatment in the market. Competitors include Takeda's Takhzyro (lanadelumab) and BioCryst's Orladeyo (berotralstat).
- JOENJA (leniolisib): JOENJA is a PI3Ku03b4 inhibitor for Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS). It's positioned to capture significant market share in this niche rare disease. There are currently few other direct competitors for APDS, but it is subject to physician's and patient's choice as well as their assessment of its attributes.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. Focus is placed on innovative products for rare and immune disorders.
Positioning
Pharming is a focused biopharmaceutical company specializing in rare disease treatments. Its competitive advantage lies in its expertise in recombinant protein technology and commercial success of RUCONEST.
Total Addressable Market (TAM)
The total addressable market for HAE and APDS treatments is substantial and expanding as diagnosis and treatment options improve. Pharming is well-positioned to capture a growing share of this market due to its established product and innovative pipeline.
Upturn SWOT Analysis
Strengths
- Established product (RUCONEST) with proven efficacy
- Specialized expertise in recombinant protein technology
- Approved product for APDS (JOENJA)
- Expanding commercial infrastructure in the U.S.
- Strong intellectual property position
Weaknesses
- Reliance on RUCONEST for majority of revenue
- Risk of competition from other HAE therapies
- High R&D costs
- Dependence on regulatory approvals
- Geographic concentration of revenue
Opportunities
- Expanding RUCONEST's market share
- Further development and commercialization of leniolisib
- Acquisition or licensing of new products for rare diseases
- Geographic expansion to new markets
- Further expanding product offerings for HAE
Threats
- Competition from established pharmaceutical companies
- Patent expiry of key products
- Unfavorable regulatory changes
- Pricing pressures from payers
- Clinical trial failures
Competitors and Market Share
Key Competitors
- TAK (TAKEDA PHARMACEUTICAL COMPANY LIMITED)
- BCRX (BIOCRYST PHARMACEUTICALS INC)
- CSL (CSL LIMITED)
Competitive Landscape
Pharming faces competition from larger, more established pharmaceutical companies. However, its focus on rare diseases and its expertise in recombinant protein technology provide a competitive edge.
Major Acquisitions
All commercial rights to RUCONEST in the U.S.
- Year: 2022
- Acquisition Price (USD millions): 125
- Strategic Rationale: Gained full control over the commercialization of its key product in the important U.S. market, enabling revenue growth and strategic flexibility.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased sales of RUCONEST and its expansion into new markets.
Future Projections: Future growth is expected to be driven by continued RUCONEST sales, the successful commercialization of leniolisib, and potential acquisitions or licensing deals.
Recent Initiatives: Recent initiatives include the U.S. commercial expansion, the launch of leniolisib, and ongoing clinical trials for new indications.
Summary
Pharming Group NV is a biopharmaceutical company focused on rare diseases with a leading product in RUCONEST. Its growth is fueled by expansion into new markets and successful commercialization of leniolisib. The company faces competition from larger firms and regulatory risks. Successful management of these risks and continued innovation will be crucial. Expansion of its product portfolio is key for long term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pharming Group NV Investor Relations
- Company SEC Filings
- Third-party Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Actual results may vary. Market share percentages are estimated and may not reflect precise figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharming Group NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-12-23 | CEO & Executive Director Mr. Fabrice Chouraqui Ph.D., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 404 | Website https://www.pharming.com |
Full time employees 404 | Website https://www.pharming.com | ||
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.